Novavax Inc

Financials

Übersicht Finanzbericht Statistik Dividenden

Mittelzufluss aus laufender Geschäftstätigkeit -173.16 M-185.5 M-127.46 M107.8 M-39.48 M -244.63 M Mittelzufluss aus Investitionstätigkeit 144.01 M-73.32 M111.1 M-136.53 M20.48 M -78.27 M Zahlungsströme aus der Finanzierungstätigkeit -3.42 M-7.06 M-1.04 M42.44 M-6.6 M 27.74 M Freier Cashflow -175.41 M-187.1 M-127.99 M105.79 M-41.72 M -251.02 M

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

NVAX

Financials

Novavax Inc

Nachrichten

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

Novavax-Aktie legt zu: Aktivistischer Investor fordert Vorstandsumbau und strategische Wende

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Routine Vaccines Okay For Now: Investment Implications Of The Court Decision (XLV)

Jefferies bekräftigt "Buy" für Novavax: Adjuvans-Plattform im Fokus

Jefferies reiterates Buy on Novavax stock, cites adjuvant platform

Novavax auf Leerink-Konferenz: Strategische Neuausrichtung angekündigt

Novavax at Leerink Global Healthcare Conference: Strategic Shift in Focus

Novavax at TD Cowen Conference: Strategic Shift to Adjuvant Licensing

Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript